Coherus Oncology (CHRS) Other financing activities (2014 - 2026)

Coherus Oncology has disclosed Other financing activities across 13 years of filings, most recently posting $150000.0 for Q2 2026.

• In Q2 2026, Other financing activities changed N/A year-over-year to $150000.0; the TTM figure through Jun 2026 stood at $9.0 million (changed N/A YoY), while the FY2025 annual figure was $7.9 million, up 752.48% from the prior year.
• Other financing activities came in at $150000.0 for Q2 2026 at Coherus Oncology, up from $52000.0 in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $8.7 million in Q4 2025 to a low of -$353000.0 in Q1 2023.
• Average Other financing activities over 5 years is $1.1 million, with a median of $472000.0 recorded in 2023.
• Year-over-year, Other financing activities tumbled 164.89% in 2023 and jumped 3529.88% in 2025.
• Over 5 years, Other financing activities stood at $665000.0 in 2022, then slipped by 29.02% to $472000.0 in 2023, then plunged by 48.94% to $241000.0 in 2024, then jumped by 3529.88% to $8.7 million in 2025, then slumped by 98.29% to $150000.0 in 2026.
• Per Business Quant data, the three most recent Other financing activities figures were $150000.0 in Q2 2026, $52000.0 in Q1 2026, and $8.7 million in Q4 2025.